Maze Therapeutics, Inc./$MAZE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Maze Therapeutics, Inc.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
- Ticker
- $MAZE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- South San Francisco, United States
- Website
- www.mazetx.com
MAZE Metrics
BasicAdvanced
$1.7B
-
-$2.67
-
-
Price and volume
Market cap
$1.7B
52-week high
$53.65
52-week low
$21.95
Average daily volume
744K
Financial strength
Current ratio
14.138
Quick ratio
13.882
Long term debt to equity
0.128
Total debt to equity
0.139
Interest coverage (TTM)
-59.22%
Profitability
EBITDA (TTM)
-162.445
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-757.36%
Operating margin (TTM)
-820.82%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-21.98%
Return on equity (TTM)
-37.49%
Valuation
Price to revenue (TTM)
89.148
Price to book
4.13
Price to tangible book (TTM)
4.13
Price to free cash flow (TTM)
-15.469
Free cash flow yield (TTM)
-6.46%
Free cash flow per share (TTM)
-2.028
Growth
Earnings per share change (TTM)
-21.21%
What the Analysts think about MAZE
Analyst ratings (Buy, Hold, Sell) for Maze Therapeutics, Inc. stock.
Analyst projections of the future price of Maze Therapeutics, Inc. stock.
Bulls say / Bears say
MZE829 has shown an encouraging early signal: in 12 evaluable patients, the company reported a 36% average reduction in urine albumin, with half achieving a reduction of at least 30%. It also reported no serious adverse events in the interim dataset. (U.S. Securities and Exchange Commission)
MZE782 produced a 42-fold increase in urinary phenylalanine excretion at a Phase 1 dose, and its Phase 2 PKU trial is now enrolling. A separate Phase 2 study in CKD is planned, giving the same drug candidate more than one potential route to value. (U.S. Securities and Exchange Commission)
Maze had $477 million in cash and marketable securities at the end of September and expects funding into 2029. That should support several upcoming clinical milestones without an immediate need to raise capital. (U.S. Securities and Exchange Commission)
The MZE829 efficacy case still rests on an interim readout from just 12 evaluable patients, and the study is not yet a definitive test of benefit. The larger dataset is due in early 2027, so the signal could weaken as more patients are assessed. (U.S. Securities and Exchange Commission)
Maze faces a well-funded rival in Vertex: its pivotal AMPLITUDE study of an APOL1 inhibitor is fully enrolled, with an interim readout expected in early 2027. That programme could establish efficacy or regulatory precedent before MZE829 reaches a pivotal trial. (Biotech Distilled)
Maze remains pre-revenue and loss-making, with its third-quarter net loss widening to $48 million from $30.1 million a year earlier as research and development spending rose. Continued clinical investment will consume cash before any product sales are assured. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 15 Nov 2026.
MAZE Financial Performance
Revenues and expenses
MAZE Earnings Performance
Company profitability
Upcoming events
No upcoming events
MAZE News
AllArticlesVideos
Funds containing MAZE
Fund name | Fund size | $MAZE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.12% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.05% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
